Structure Therapeutics Inc. ADR (GPCR) News
Filter GPCR News Items
GPCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GPCR News Highlights
- For GPCR, its 30 day story count is now at 9.
- Over the past 14 days, the trend for GPCR's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- The most mentioned tickers in articles about GPCR are DRUG, CRSP and GLP.
Latest GPCR News From Around the Web
Below are the latest news stories about STRUCTURE THERAPEUTICS INC that investors may wish to consider to help them evaluate GPCR as an investment opportunity.
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying NowIt has genuine struggles ahead, but it has some actual value in hand as well. |
7 Small-Cap Stocks That Wall Street Loves for Good ReasonThe market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading |
7 Small-Cap Stocks That Wall Street Loves for Good ReasonAs we head into 2024, it’s common for investors to look back on 2023. Much of this year had investors in a defensive posture. Small-cap stocks lagged sharply behind the broader market. However, the market rally that started in November is showing signs of broadening to include small-cap stocks. But which ones are ready to shine in 2024? One place for you to start your research is in the stocks that are receiving upgrades from analysts. The market is forward-looking, and analysts are a significan |
Structure Plummets 43% After Trailing Lilly In Obesity TreatmentStructure's potential rival to Lilly in weight-loss drugs missed expectations on Monday, and GPCR stock took an absolute beating. |
Another Drugmaker Hits Rocks Seeking a Weight-Loss PillDemocratizing the [weight-loss drug revolution](https://www.wsj.com/articles/weight-loss-drug-ozempic-gold-rush-baf849bd) is proving harder than anticipated—and costing companies on Wall Street. Biotech Structure Therapeutics on Monday released disappointing study data for its weight-loss pill GSBR-1290, sending its U. |
New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.Biotech Structure saw shares dive after the firm disclosed disappointing data for an experimental obesity pill. |
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical StudyGSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% study discontinuation rate due to adverse events in obesity Topline Phase 2a data from first study in type 2 diabetes mellitus (T2DM) demonstrate significant reductions in hemoglobin A1c (HbA1c) and weight at 12 weeks Interim Phase 2a data from obesity cohort demonstrate significant reduction in weigh |
Structure Therapeutic obesity pill shows promise in mid-stage trialBiotechnology company Structure Therapeutics on Monday said its experimental diabetes and obesity pill had promising results in a mid-stage trial, showing a nearly 5% weight loss in obese patients after eight weeks of treatment. The pill - called GSBR-1290 by Structure - belongs to the same class of diabetes and obesity treatments as Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Mounjaro and Zepbound, known as GLP-1 agonists. The company said the Phase 2a study was of 94 patients, divided into a cohort with obesity and a cohort with type 2 diabetes. |
Structure shares sink as obesity pill misses expectations in small studyResults from a Phase 2 trial fell short of what’s been seen with a similar Eli Lilly medicine, causing the closely watched biotech’s shares to plummet. |
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023Some of the most explosive opportunities can be found in biotech stocks. |